MRK

Merck & Co Inc

Add to Watchlist

Advanced Chart

82.460

+2.16(2.690%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

82.590

Open

80.750

VWAP

81.68

Vol

4.25M

Mkt Cap

200.57B

Low

80.480

Amount

347.55M

EV/EBITDA(TTM)

8.16

Total Shares

2.50B

227.42B

EV/OCF(TTM)

12.27

P/S(TTM)

3.19

Merck & Co., Inc. is a global health care company that delivers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. The Company's segments include Pharmaceutical and Animal Health. Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Company sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. It sells its human health vaccines primarily to physicians, wholesalers, distributors and government entities. Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species. It sells its products to veterinarians, distributors, animal producers, farmers and pet owners.

Intellectia.AI: Fast-Track Your Stock Wins

Loved by 300K+ users. Get precise AI signals to ride market trends in minutes!

Intellectia.AI: Fast-Track Your Stock Wins

Loved by 300K+ users. Get precise AI signals to ride market trends in minutes!

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

15.92B

+2.54%

2.272

+2.33%

16.32B

+4.47%

2.208

+28.37%

17.01B

+2.12%

2.366

+50.72%

Estimates Revision

The market is revising Downward the revenue expectations for Merck & Co., Inc. (MRK) for FY2025, with the revenue forecasts being adjusted by -0.26% over the past three months. During the same period, the stock price has changed by 7.61%.

Revenue Estimates for FY2025

Revise Downward

-0.26%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-0.2%

In Past 3 Month

Stock Price

Go Up

+7.61%

In Past 3 Month

17 Analyst Rating

23.05% Upside

Wall Street analysts forecast MRK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MRK is 101.47 USD with a low forecast of 82.00 USD and a high forecast of 141.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

10 Buy

7 Hold

0 Sell

Moderate Buy

23.05% Upside

Current: 82.460

Low

82.00

Averages

101.47

High

141.00

23.05% Upside

Current: 82.460

Low

82.00

Averages

101.47

High

141.00

Morgan Stanley

Terence Flynn

Equal Weight

downgrade

$99 -> $98

2025-07-10

Reason

Morgan Stanley

Terence Flynn

Price Target

$99 -> $98

2025-07-10

downgrade

Equal Weight

Reason

Morgan Stanley analyst Terence Flynn lowered the firm's price target on Merck to $98 from $99 and keeps an Equal Weight rating on the shares. Year-to-date, large cap pharma and biotech companies have both underperformed given the macro environment, while multiple areas of policy uncertainty remain, including drug pricing dynamics, tariff and transfer pricing exposure, and FDA staffing changes, the analyst tells investors in a research note.

Citi

Buy -> Neutral

downgrade

$115 -> $84

2025-05-14

Reason

Citi

Price Target

$115 -> $84

2025-05-14

downgrade

Buy -> Neutral

Reason

Citi downgraded Merck to Neutral from Buy with a price target of $84, down from $115. While the company's growth headwinds from the Keytruda loss of exclusivity in 2028 are "well-appreciated," offsets from Merck's pipeline progression and new launches "are taking time," the analyst tells investors in a research note. The firm says that despite a strong balance sheet, Merck seems to have less urgency towards business development to offset the 10%-20% Keytruda sales declines post the loss of exclusivity. The "clock is ticking" for the company's pipeline assets to commercially scale, contends Citi.

BMO Capital

Evan Seigerman

Market Perform

downgrade

$89 -> $82

2025-04-25

Reason

BMO Capital

Evan Seigerman

Price Target

$89 -> $82

2025-04-25

downgrade

Market Perform

Reason

BMO Capital analyst Evan Seigerman lowered the firm's price target on Merck to $82 from $89 and keeps a Market Perform rating on the shares after its Q1 results and FY25 guidance cut. The firm warns that further Gardasil headwinds complicate Merck's potential to regain its footing, adding that while the FDA labeling changes are unlikely, ACIP recommendation changes could meaningfully negatively impact long-term U.S. revenue, the analyst tells investors in a research note.

Cantor Fitzgerald

Carter Gould

Hold

Initiates

$85

2025-04-22

Reason

Cantor Fitzgerald

Carter Gould

Price Target

$85

2025-04-22

Initiates

Hold

Reason

Guggenheim

Vamil Divan

Strong Buy

Reiterates

$115

2025-04-17

Reason

Guggenheim

Vamil Divan

Price Target

$115

2025-04-17

Reiterates

Strong Buy

Reason

Deutsche Bank

James Shin

Strong Buy

Hold

Downgrades

$128 → $105

2025-02-18

Reason

Deutsche Bank

James Shin

Price Target

$128 → $105

2025-02-18

Downgrades

Strong Buy

Hold

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Merck & Co Inc (MRK.N) is 8.76, compared to its 5-year average forward P/E of 17.10. For a more detailed relative valuation and DCF analysis to assess Merck & Co Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Fair

5Y Average PE

17.10

Current PE

8.76

Overvalued PE

31.81

Undervalued PE

2.40

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Fair

5Y Average EV/EBITDA

11.77

Current EV/EBITDA

7.04

Overvalued EV/EBITDA

16.70

Undervalued EV/EBITDA

6.84

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Undervalued

5Y Average PS

4.12

Current PS

3.03

Overvalued PS

4.67

Undervalued PS

3.57

Trade Smarter with Intellectia.AI

300K+ trust us for AI trading signals that capture market momentum early!

Trade Smarter with Intellectia.AI

300K+ trust us for AI trading signals that capture market momentum early!

Financials

Annual

Quarterly

FY2025Q2

YoY :

-1.90%

15.81B

Total Revenue

FY2025Q2

YoY :

-8.34%

5.71B

Operating Profit

FY2025Q2

YoY :

-18.92%

4.43B

Net Income after Tax

FY2025Q2

YoY :

-17.76%

1.76

EPS - Diluted

FY2025Q2

YoY :

-47.81%

2.53B

Free Cash Flow

FY2025Q2

YoY :

+1.24%

78.13

Gross Profit Margin - %

FY2025Q2

YoY :

-17.35%

28.01

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

352.7K

USD

6-9

Months

1.4M

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

1.6M

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

266.0

Volume

3-6

Months

556.6K

Volume

6-9

Months

840.7K

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

510.5K

Volume

Months

6-9

4.2M

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress areSelling! The selling amount has increased105.62%over the last month.

Sold

0-3

Months

183.0K

USD

3-6

Months

210.5K

USD

6-9

Months

154.0K

USD

0-12

Months

123.5K

USD

Bought

0-3

8.0K

USD

Months

3-6

338.5K

USD

Months

6-9

146.0K

USD

Months

0-12

16.0K

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

352.7K

USD

6-9

Months

1.4M

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

1.6M

USD

Months

0-12

0.0

USD

Months

Unlock Winning Stocks with Intellectia.AI

Trusted by 300K+ investors. Get AI-driven trading signals to seize opportunities fast!

Unlock Winning Stocks with Intellectia.AI

Trusted by 300K+ investors. Get AI-driven trading signals to seize opportunities fast!

MRK News & Events

Events Timeline

2025-08-12 (ET)

2025-08-12

05:39:52

Merck announces topline results from KEYNOTE-905 trial

2025-08-08 (ET)

2025-08-08

09:29:30

Trump, pharma industry discuss increasing medicine spending abroad, Reuters says

2025-08-05 (ET)

2025-08-05

16:26:48

Janux Therapeutics reaches clinical milestone in Merck TRACTr collaboration

News

9.0

09:00 AMNASDAQ.COM

PinnedHealth Canada Approves Merck's Keytruda For Patients With Resectable Locally Advanced HNSCC

9.0

08-12Newsfilter

PinnedKEYTRUDA® (pembrolizumab) plus Padcev® (enfortumab vedotin-ejfv) Significantly Improved Event-Free and Overall Survival and Pathologic Complete Response Rate for Certain Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery

9.0

12:00 PMNASDAQ.COM

Will Zanzalintinib Ease Out EXEL's Reliance on Cabometyx for Growth?